August 13, 2021 09:52 AM EDTUpdated 11:57 AM

Robert Bazemore makes Hutchmed deal his grand finale as Epizyme CEO; Black Diamond reshuffles the deck with departures of CMO, CSO

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Paul Schloesser

Associate Editor

→ One minute, Epizyme CEO Robert Bazemore helped engineer a partnership with Hutchmed on developing Tazverik in China. The next minute, he gave his job …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Robert Bazemore makes Hutchmed deal his grand finale as Epizyme CEO; Black Diamond reshuffles the deck with departures of CMO, CSO

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Are programs with compounded GLP-1s safe for your population?

Robert Baze­more makes Hutchmed deal his grand fi­nale as Epizyme CEO; Black Di­a­mond reshuf­fles the deck with de­par­tures of CMO, CSO

Copy Chief

Editor

Associate Editor

Sign up to read this article for free.

Robert Bazemore makes Hutchmed deal his grand finale as Epizyme CEO; Black Diamond reshuffles the deck with departures of CMO, CSO